Living meta-analysis and evidence synthesis of therapies for COVID-19

click on circles to display study description...

ACTIV-2 (BRII-196 and BRII-198), 0 NCT04518410

amubarvimab/romlusevimab (BRII-196 and BRII-198-Brii Biosciences) (n=418) vs. placebo (n=419)

randomized controlled trial   risk of bias NA

Studied treatment

BRII-196/BRII-198

Control treatment

placebo

Patients

COVID 19 outpatients

Method

Remark

results from interim analysis; divulged in a press release dated on October and December, 2021 *Warning! The spread of new Sars-Cov2 variants is constantly evolving, this study was performed in a different viral context than today, its results should be interpreted accordingly.*